MSH|^~\&|MIC|ARH|||201910291753||ORU^R01|4093276|D|2.3|||AL|NE
PID|1||AB00008278|AB8184|LABTESTBEAGLE^LUMED^||19700302|F||||||||||AB000558/19|9874974645
OBR|1|34602^MIC|00026590^19:X0000059R^MIC^19:X59^34602|800.5000^MRSA^MRSA culture^^^13317-3||201910290807|201910290803|||||||201910290803|Nares - bilateral^^^|||||||||MB|F||||
OBX|1|CE|800.5000^MRSA^MRSA culture^^^13317-3^O:MRSA|1.1|MRSA^Staphylococcus aureus-MRSA||||||F|||201910291753
OBX|2|ST|800.5000^MRSA^MRSA culture^^^13317-3^P:AMT|1.1|||||||F|||201910291753
OBX|3|ST|800.5000^MRSA^MRSA culture^^^13317-3^R:4|1.1|4+||||||F|||201910291753
OBR|2||00026590^19:X0000059R^MIC^19:X59^34602|913.2500^P580^Vitek P580 Sensitivity^^^29576-6||201910290807|201910290803|||||||201910290803|Nares - bilateral^^^|||||||||MB|F|MRSA^1.1|||34602^MIC
OBX|1|ST|101.000^CFZ^Cefazolin^^76-0^76-0|||||R|||F|||201910291753
OBX|2|ST|101.100^CF^Cephalexin^^149-5^149-5|||||R|||F|||201910291753
OBX|3|ST|200.000^AUG^Amoxicillin/Clavulanate^^20-8^20-8|||||R|||F|||201910291753
OBX|4|ST|200.600^OX^Cloxacillin^^197-4^197-4|||||R|||F|||201910291753
OBX|5|ST|400.200^E^Erythromycin^^233-7^233-7|||||S|||F|||201910291753
OBX|6|ST|400.300^CD^Clindamycin^^193-3^193-3|||||S|||F|||201910291753
OBX|7|ST|600.000^TS^Trimethoprim/sulfamethoxazole^^516-5^516-5|||||S|||F|||201910291753
OBX|8|ST|700.000^TE^Tetracycline^^496-0^496-0|||||S|||F|||201910291753
OBX|9|ST|700.100^DOX^Doxycycline^^225-3^225-3|||||S|||F|||201910291753
OBX|10|ST|800.000^VA^Vancomycin^^524-9^524-9|||||S|||F|||201910291753

MSH|^~\&|MIC|SMH|||201910251451||ORU^R01|4090650|D|2.3|||AL|NE
PID|1||SM00046785|SM46576|LABTESTPOODLE^LUMED^||19501206|M||||||||||SM003264/19|9874955226
OBR|1|3454811^MIC|0002655311^19:Mrsa_Negative1^MIC^19:X55^3454811|800.5000^MRSA^MRSA culture^^^13317-3||201910251419|201910251414|||||||201910251414|Groin - bilateral^^^|||||||||MB|F||||
OBX|1|ST|800.5000^MRSA^MRSA culture^^^13317-3^S:NMRSA|1|||||||F|||201910251451
NTE|1||No methicillin resistant Staphylococcus aureus (MRSA)
NTE|2||isolated.

MSH|^~\&|MIC|SMH|||201910251451||ORU^R01|4090650|D|2.3|||AL|NE
PID|1||SM00046785|SM46576|LABTESTPOODLE^LUMED^||19501206|M||||||||||SM003264/19|9874955226
OBR|1|34548^MIC|00026553^19:Mrsa_Negative2^MIC^19:X55^34548|800.5000^MRSA^MRSA culture^^^13317-3||201910251419|201910251414|||||||201910251414|Groin - bilateral^^^|||||||||MB|F||||
OBX|1|ST|800.5000^MRSA^MRSA culture^^^13317-3^S:NMRSA|1|No Methicillin Resistant Staphylococcus aureus (MRSA)||||||F|||201910251451
OBX|2|ST|800.5000^MRSA^MRSA culture^^^13317-3^S:NMRSA|1|isolated.||||||F|||201910251451

MSH|^~\&|MIC|FCC|||201912091211||ORU^R01|4125823|D|2.3|||AL|NE
PID|1||FB00000539|FB534|PHATEST^FCC1^|||F||||||||||FA000007/19|
OBR|1|36587^MIC|00027734^19:B0000347R^MIC^19:B347^36587|100.5005^BC^Blood culture^^^600-7||201912091141|201912081600|||||||201912081605|Blood^^^Peripheral|||||||||MB|I||||
OBX|1|CE|100.5010^BCT^Blood culture^^6463-4^600-7^O:MRSA|1.1|MRSA^Staphylococcus aureus-MRSA||||||P|||201912091211
OBR|2||00027734^19:B0000347R^MIC^19:B347^36587|913.2500^P580^Vitek P580 Sensitivity^^^29576-6||201912091141|201912081600|||||||201912081605|Blood^^^Peripheral|||||||||MB|P|6463-4^1.1|||36587^MIC
OBX|1|ST|101.000^CFZ^Cefazolin^^76-0^76-0|||||R|||P|||201912091211
OBX|2|ST|200.600^OX^Cloxacillin^^197-4^197-4|||||R|||P|||201912091211
OBX|3|ST|800.000^VA^Vancomycin^^524-9^524-9|||||S|||P|||201912091211

MSH|^~\&|MIC|SMH|||201910251452||ORU^R01|4090660|D|2.3|||AL|NE
PID|1||SM00046785|SM46576|LABTESTPOODLE^LUMED^||19501206|M||||||||||SM003264/19|9874955226
OBR|1|34549^MIC|00026553^19:X0000057R^MIC^19:X57^34549|800.3900^VREREQ^VRE Request^^X10416^XXX-2723||201910251419|201910251414|||||||201910251414|Rectal^^^|||||||||MB|F||||
OBX|1|ST|800.3900^VREREQ^VRE Request^^X10416^XXX-2723^P:VREREQ|1|             VRE Request:||||||F|||201910251452
OBX|2|ST|800.3900^VREREQ^VRE Request^^X10416^XXX-2723^R:A|1|Approved by Microbiologist||||||F|||201910251452
OBR|2|34549^MIC|00026553^19:X0000057R^MIC^19:X57^34549|800.4000^VRE^VRE screen^^^13316-5||201910251419|201910251414|||||||201910251414|Rectal^^^|||||||||MB|F||||
OBX|1|ST|800.4000^VRE^VRE screen^^^13316-5^S:NVRE|2|No Vancomycin Resistant Enterococcus (VRE) isolated.||||||F|||201910251452
OBR|3|34549^MIC|00026553^19:X0000057R^MIC^19:X57^34549|800.5700^MDRO^Multiresistant organism screen^^^XBC3337-4||201910251419|201910251414|||||||201910251414|Rectal^^^|||||||||MB|F||||
OBX|1|ST|800.5800^MDRO R^Multiresistant organism screen^^11502-2A^XBC3337-4^S:NCPE|3|Negative for carbapenemase producing Enterobacteriaceae||||||F|||201910251452
OBX|2|ST|800.5800^MDRO R^Multiresistant organism screen^^11502-2A^XBC3337-4^S:NCPE|3|(CPE).||||||F|||201910251452

MSH|^~\&|MIC|ARH|||201910291758||ORU^R01|4093277|D|2.3|||AL|NE
PID|1||AB00008278|AB8184|LABTESTBEAGLE^LUMED^||19700302|F||||||||||AB000558/19|9874974645
OBR|1|34603^MIC|00026590^19:MT0000181R^MIC^19:MT181^34603|700.1950^CDT^C. difficile Assay^^^XXX-2144||201910290807|201910290803|||||||201910290803|Stool^^^|||||||||MB|F||||
OBX|1|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|Patients positive for the C. difficile toxin B gene should||||||F|||201910291758
OBX|2|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|not have a test of cure as the test may remain positive for||||||F|||201910291758
OBX|3|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|months after symptom resolution.||||||F|||201910291758
OBX|4|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|Approximately 25% of adequately treated patients will have a||||||F|||201910291758
OBX|5|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|relapse of C. difficile disease. Repeat C. difficile testing||||||F|||201910291758
OBX|6|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|is not helpful.||||||F|||201910291758
OBX|7|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|||||||F|||201910291758
OBX|8|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|A copy of these results has been sent to Infection||||||F|||201910291758
OBX|9|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|Prevention and Control.||||||F|||201910291758
OBX|10|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|||||||F|||201910291758
OBX|11|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|For mild or first recurrent Clostridium difficile associated||||||F|||201910291758
OBX|12|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|diarrhea in adults, treatment with oral vancomycin is now||||||F|||201910291758
OBX|13|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|considered more effective than metronidazole.  Consult||||||F|||201910291758
OBX|14|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|Infectious Disease Society of America (IDSA) 2017||||||F|||201910291758
OBX|15|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|C.difficile guideline or UpToDate.||||||F|||201910291758

MSH|^~\&|MIC|SMH|||201911251500||ORU^R01|4112534|D|2.3|||AL|NE
PID|1||SM00046785|SM46576|LABTESTPOODLE^LUMED^||19501206|M||||||||||SM003264/19|9874955226
OBR|1|35283^MIC|00027096^19:MT0000208R^MIC^19:MT208^35283|700.1950^CDT^C. difficile Assay^^^XXX-2144||201911191433|201911191427|||||||201911191427|Stool^^^|||||||||MB|F||||
OBX|1|CE|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8^O:CDIF|1.1|CDIF^Clostridium difficile||||||F|||201911251500

MSH|^~\&|MIC|SMH|||201911291414||ORU^R01|4117866|D|2.3|||AL|NE
PID|1||SM00040180|SM40149|MICTEST^DELIGHTED^||20100925|M||||||||||SM005007/18|9876490648
OBR|1|36293^MIC|00027517^19:MT0000235R^MIC^19:MT235^36293|700.1950^CDT^C. difficile Assay^^^XXX-2144||201911291414|201911291414|||||||201911291414|Stool^^^|||||||||MB|F||||
OBX|1|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8^S:TNP|1|Test not performed||||||F|||201911291414

MSH|^~\&|MIC|SMH|||201911291415||ORU^R01|4117867|D|2.3|||AL|NE
PID|1||SM00045635|SM45433|MICTEST^MUFFIN^||19660210|F||||||||||SM001865/19|9875099847
OBR|1|36294^MIC|00027518^19:MT0000236R^MIC^19:MT236^36294|700.1950^CDT^C. difficile Assay^^^XXX-2144||201911291414|201911291414|||||||201911291414|Stool^^^|||||||||MB|F||||
OBX|1|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8^S:NSQ|1|Insufficient quant.||||||F|||201911291415

MSH|^~\&|MIC|SMH|||201911291418||ORU^R01|4117871|D|2.3|||AL|NE
PID|1||SM00040180|SM40149|MICTEST^DELIGHTED^||20100925|M||||||||||SM005007/18|9876490648
OBR|1|36295^MIC|00027519^19:MT0000237R^MIC^19:MT237^36295|700.1950^CDT^C. difficile Assay^^^XXX-2144||201911291417|201911291417|||||||201911291417|Stool^^^|||||||||MB|F||||
OBX|1|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8^S:NG|1|No growth||||||F|||201911291418

MSH|^~\&|MIC|SMH|||201911261457||ORU^R01|4113665|D|2.3|||AL|NE
PID|1||SM00047031|SM46814|LABTESTBULLDOG^LUMED^||20151001|M||||||||||SM003630/19|9874838027
OBR|1|36131^MIC|00027377^19:MT0000228R^MIC^19:MT228^36131|800.1500^FLURSV^FLU A/B \T\ RSV PCR (FH)^^^XBC4608-4||201911261454|201911261200|||||||201911261454|Nasopharyngeal washing^^^|||||||||MB|F||||
OBX|1|CE|800.1501^FLURSV R^FLU A/B \T\ RSV PCR (FH)^^XBC4608-4^XBC4608-4^O:NATFLUA|1.1|NATFLUA^Influenza A detected||||||F|||201911261457
OBX|2|ST|800.1501^FLURSV R^FLU A/B \T\ RSV PCR (FH)^^XBC4608-4^XBC4608-4|1.1|||||||F|||201911261457
NTE|1||The molecular assay is capable of detecting Influenza A,
NTE|2||Influenza B, and Respiratory Syncytial Virus.
NTE|3||
NTE|4||This specimen will be stored for 2 weeks. If testing for
NTE|5||additional respiratory pathogens is required, please contact
NTE|6||the Medical Microbiologist.

MSH|^~\&|MIC|FCH|||201911261310||ORU^R01|4113357|D|2.3|||AL|NE
PID|1||FC00002120|FC2172|PHATEST^CELERY^||19991120|M||||||||||FC000040/19|9874854924
OBR|1|36108^MIC|00027358^19:MT0000227R^MIC^19:MT227^36108|800.1500^FLURSV^FLU A/B \T\ RSV PCR (FH)^^^XBC4608-4||201911261235|201911250900|||||||201911261235|Nasopharyngeal swab^^^|||||||||MB|F||||
OBX|1|ST|800.1501^FLURSV R^FLU A/B \T\ RSV PCR (FH)^^XBC4608-4^XBC4608-4|1|||||||F|||201911261310
NTE|1||No virus detected using a molecular assay capable of
NTE|2||detecting Influenza A, Influenza B, and Respiratory
NTE|3||Syncytial Virus.
NTE|4||
NTE|5||This specimen will be stored for 2 weeks. If testing for
NTE|6||additional respiratory pathogens is required, please contact
NTE|7||the Medical Microbiologist.

MSH|^~\&|MIC|CAC|||201911290834||ORU^R01|4117339|D|2.3|||AL|NE
PID|1||CZ00001004|CZ1004|PHATEST^CZ1^|||M||||||||||CZ000001/19|
OBR|1|36267^MIC|00027495^19:MT0000232R^MIC^19:MT232^36267|800.1500^FLURSV^FLU A/B \T\ RSV PCR (FH)^^^XBC4608-4||201911290814|201911280800|||||||201911290814|Nasopharyngeal aspirate^^^|||||||||MB|F||||
OBX|1|CE|800.1501^FLURSV R^FLU A/B \T\ RSV PCR (FH)^^XBC4608-4^XBC4608-4^O:NATFLUB|1.1|NATFLUB^Influenza B detected||||||F|||201911290834
OBX|2|ST|800.1501^FLURSV R^FLU A/B \T\ RSV PCR (FH)^^XBC4608-4^XBC4608-4|1.1|||||||F|||201911290834
NTE|1||The molecular assay is capable of detecting Influenza A,
NTE|2||Influenza B, and Respiratory Syncytial Virus.
NTE|3||
NTE|4||This specimen will be stored for 2 weeks. If testing for
NTE|5||additional respiratory pathogens is required, please contact
NTE|6||the Medical Microbiologist.

MSH|^~\&|MIC|ARH|||201910290808||ORU^R01|4092429|D|2.3|||AL|NE
PID|1||AB00008278|AB8184|LABTESTBEAGLE^LUMED^||19700302|F||||||||||AB000558/19|9874974645
OBR|1|34601^MIC|00026590^19:X0000058R^MIC^19:X58^34601|800.3900^VREREQ^VRE Request^^X10416^XXX-2723||201910290807|201910290803|||||||201910290803|Colostomy site^^^|||||||||MB|F||||
OBX|1|ST|800.3900^VREREQ^VRE Request^^X10416^XXX-2723^P:VREREQ|1|             VRE Request:||||||F|||201910290808
OBX|2|ST|800.3900^VREREQ^VRE Request^^X10416^XXX-2723^R:A|1|Approved by Microbiologist||||||F|||201910290808

MSH|^~\&|MIC|ARH|||201910290821||ORU^R01|4092431|D|2.3|||AL|NE
PID|1||AB00008278|AB8184|LABTESTBEAGLE^LUMED^||19700302|F||||||||||AB000558/19|9874974645
OBR|1|34601^MIC|00026590^19:X0000058R^MIC^19:X58^34601|800.3900^VREREQ^VRE Request^^X10416^XXX-2723||201910290807|201910290803|||||||201910290803|Colostomy site^^^|||||||||MB|F||||
OBX|1|ST|800.3900^VREREQ^VRE Request^^X10416^XXX-2723^P:VREREQ|1|             VRE Request:||||||F|||201910290808
OBX|2|ST|800.3900^VREREQ^VRE Request^^X10416^XXX-2723^R:A|1|Approved by Microbiologist||||||F|||201910290808
OBR|2|34601^MIC|00026590^19:X0000058R^MIC^19:X58^34601|800.4000^VRE^VRE screen^^^13316-5||201910290807|201910290803|||||||201910290803|Colostomy site^^^|||||||||MB|F||||
OBX|1|CE|800.4000^VRE^VRE screen^^^13316-5^O:EAVI|2.1|EAVI^Enterococcus avium||||||F|||201910290821
OBX|2|ST|800.4000^VRE^VRE screen^^^13316-5^P:AMT|2.1|||||||F|||201910290821
OBX|3|ST|800.4000^VRE^VRE screen^^^13316-5^R:4|2.1|4+||||||F|||201910290821
OBX|4|ST|800.4000^VRE^VRE screen^^^13316-5|2.1|||||||F|||201910290821
NTE|1||Vancomycin Resistant Enterococci (VRE).  A copy of the
NTE|2||results has been sent to Infection Control.
OBR|3||00026590^19:X0000058R^MIC^19:X58^34601|913.1500^GP67^Vitek GP67 Sensitivity^^^29576-6||201910290807|201910290803|||||||201910290803|Colostomy site^^^|||||||||MB|F|VRE^2.1|||34601^MIC

MSH|^~\&|MIC|SMH|||202004132144||ORU^R01|1428428436|P|2.3|||AL|NE
PID|1||AB00008278|AB8184|LABTESTBEAGLE^LUMED^||19700302|F||||||||||AB000558/19|9874974645
OBR|1|48606582^MIC|29792091^20:MT0012887M^MIC^20:MT12887^48606582|700.1950^CDT^C. difficile Assay^^^XXX-2144||202004131336|202004131333|||||||202004131439|Stool^^^|||||||||MB|F||||
OBX|1|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|C.difficile -POSITIVE by molecular assay(NAT)||||||F|||202004132144
OBX|2|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|||||||F|||202004132144
NTE|1||Patients positive for the C. difficile toxin B gene should
NTE|2||not have a test of cure as the test may remain positive for
NTE|3||months after symptom resolution.
NTE|4||Approximately 25% of adequately treated patients will have a
NTE|5||relapse of C. difficile disease. Repeat C. difficile testing
NTE|6||is not helpful.
NTE|7||
NTE|8||A copy of these results has been sent to Infection
NTE|9||Prevention and Control.
NTE|10||
NTE|11||For mild or first recurrent Clostridium difficile associated
NTE|12||diarrhea in adults, treatment with oral vancomycin is now
NTE|13||considered more effective than metronidazole.  Consult
NTE|14||Infectious Disease Society of America (IDSA) 2017
NTE|15||C.difficile guideline or UpToDate.
NTE|16||
NTE|17||Report phoned and broadcast to: SM-5W
NTE|18||Date: 13/04/20 Time: 2142

MSH|^~\&|MIC|RCH|||202004131141||ORU^R01|1428354672|P|2.3|||AL|NE
PID|1||AB00008278|AB8184|LABTESTBEAGLE^LUMED^||19700302|F||||||||||AB000558/19|9874974645
OBR|1|48597559^MIC|29786502^20:MT0012776M^MIC^20:MT12776^48597559|700.1950^CDT^C. difficile Assay^^^XXX-2144||202004121030|202004121200|||||||202004121217|Stool^^^|||||||||MB|F||||
OBX|1|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|C.difficile -Negative by molecular assay(NAT)||||||F|||202004131141